GlucoTrack, Inc. (NASDAQ:GCTK - Get Free Report) Director Drew Sycoff acquired 182,540 shares of the company's stock in a transaction dated Monday, April 22nd. The stock was acquired at an average cost of $1.26 per share, for a total transaction of $230,000.40. Following the completion of the purchase, the director now directly owns 2,951,258 shares in the company, valued at $3,718,585.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
GlucoTrack Stock Down 37.0 %
Shares of NASDAQ:GCTK opened at $0.48 on Thursday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.22 and a quick ratio of 3.22. The business's 50-day moving average is $0.38 and its 200-day moving average is $0.28. GlucoTrack, Inc. has a 1 year low of $0.13 and a 1 year high of $1.00.
GlucoTrack (NASDAQ:GCTK - Get Free Report) last announced its quarterly earnings data on Thursday, March 28th. The company reported ($0.10) earnings per share (EPS) for the quarter.
About GlucoTrack
(
Get Free Report)
GlucoTrack, Inc, a medical device company, focuses on designing, developing, and commercializing non-invasive glucose monitoring devices for use by people with diabetes in the United States. It develops GlucoTrack, a non-invasive blood glucose monitor that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
